Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Sareena George

Interventional Cardiology Burlington, MA Medical Doctor

NPI 1689053464 CMS profile 11333197

41 Mall Rd, Burlington, MA 01805

Open in the dashboard

General payments

$57,738

56 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sareena George of Burlington, MA is reported in the CMS Open Payments database as having received $57,738 across 56 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $606 9
2024 General $188 2
2023 General $50,846 18
2022 General $6,098 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sareena George
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Sareena George were reported at $606. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Sareena George Interventional Cardiology median Middle half National median
2019 $0 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $0 $677 $233–$1,827 $132
2022 $6,098 $978 $333–$2,724 $149
2023 $50,846 $1,136 $382–$2,986 $160
2024 $188 $1,181 $395–$3,326 $164
2025 $606 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $50,395 4 payments
  2. Abbott Laboratories $5,302 8 payments
  3. Inari Medical, Inc. $970 17 payments
  4. Cardiva Medical, Inc. $226 3 payments
  5. Bolton Medical Inc $155 1 payment
  6. Thrombolex, Inc. $143 2 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $111 7 payments
  8. Stryker Corporation $93 3 payments
  9. Terumo Medical Corporation $92 1 payment
  10. Recor Medical Inc $76 1 payment
  11. Other $176 9 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Grant $54,500 2 payments
  2. Food and Beverage $2,810 51 payments
  3. Travel and Lodging $427 3 payments
Products named General payments · program years 2022–2025
  1. FLOWTRIEVER CATHETER, S $1,020 19 payments
  2. CT THROMBECTOMY SYSTEM KIT $1,020 19 payments
  3. OMNILINK ELITE $626 5 payments
  4. Cardiva VASCADE 5F VCS $226 3 payments
  5. ROTAPRO $169 1 payment
  6. COROFLOW $158 1 payment
  7. THORAFLEX HYBRID $155 1 payment
  8. AVVIGO Guidance System $150 1 payment
  9. JARDIANCE $146 9 payments
  10. Bashir Endovascular Catheter $143 2 payments
  11. Other $533 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

83

Median for Interventional Cardiology: 2,236

Drug cost

$47,513

Median for Interventional Cardiology: $380,412

Branded share of claims

48.2%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 40 $46,747
Metoprolol Succinate Generic 30 $710
Amlodipine Besylate Generic 13 $56

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$93,981

Medicare's payments for the services billed

Medicare patients

374

Average age 76

Services billed

799

157 women, 217 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 68%
Arthritis 49%
Heart failure 47%
Atrial fibrillation 43%
Chronic kidney disease 41%
Diabetes 35%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

56 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record